Prodotti GS / Area HIV 17 gennaio 2023 Trial update: Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
Prodotti competitors / Area HIV 17 gennaio 2023 Trial update: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed
Prodotti competitors / Area HIV 9 dicembre 2021 US- Merck Pauses Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
Prodotti competitors / Area HIV 19 novembre 2021 Merck Stops Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of HIV-1
